Clinical Trial

Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Study acronym: METAfoie
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches. The main question it aims to answer is: Does an individualized nutritionnal approach with a dietician combined with medication targeting obesity is the most efficient way to treat hepatic steatosis associated with obesity? Participants will either participate in one of three groups: * Nutrition: Participant will only have a regular follow-up with a registered dietician; * Nutrition + Semaglutide: Participants will start a new medication targeting obesity and will have a regular follow-up with a registered dietician; * Semaglutide: Participants will start a new medication targeting obesity.
Trial Details
NCT Number NCT06764056
Lead Sponsor Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Conditions Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity
Enrollment 120 participants
Start Date 2025-01
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-01-08